On the Nashville stage, under the bright lights of the Paradigm Shift Summit, I talked about one thing I’ve never mentioned publicly…

My own health mystery.

For the past three years, I’ve been trapped in a diagnostic Groundhog Day.

Doctors, scans, supplements, specialists… the whole parade.

Everyone had a theory, no one had an answer. Apparently, my body existed in a quantum state of “totally fine” and “good luck with that.”

Then someone told me about Function Health—an app that uses AI to decode your biomarkers like a mechanic reading your engine diagnostics.

I gave blood on a Tuesday. By Wednesday, I already had biomarkers rolling in—liver enzymes, hormones, inflammation markers—all laid out in a dashboard.

It even gave me suggestions on what to eat, what to avoid, and even which supplements might help.

For the first time in years, I had clarity.

Not just “you’re fine” or “come back in six months.” Real, measurable insight.

AI gave me a window into my symptoms the doctors hadn’t.

And the technology is only going to get better, smarter, faster, and cheaper from here.

That’s the leap most aren’t aware of yet…

AI is officially moving from “how’s my sleep?” to “let’s rewrite the entire medical industry, please.”

Case in point:

The End of Animal Testing

It’s the oldest story in biotech: test in animals, cross your fingers, hope humans don’t die.

Axiom, an AI startup, is built to leapfrog that model.

It runs high-content imaging on real human liver cells, mapping what happens when molecules hit them.

Cell death, enzyme activity, mitochondrial stress: it all goes into a giant neural network trained to see toxicity before the first trial begins.

Founder Brandon White says his model is already the most accurate predictor of liver toxicity on Earth.

At a recent Society of Toxicology conference, the company revealed results showing 77% sensitivity and 90% specificity in predicting liver toxicity.

In plain English: Axiom’s AI successfully spots most dangerous molecules while rarely crying wolf. It’s not perfect, but it’s far more efficient than traditional lab and animal tests, which are slower, costlier, and often less predictive of how a drug will behave in humans.

And the timing for Axiom couldn’t be better.

The FDA just announced it’s phasing out animal testing, meaning the industry is scrambling for human-cell and computational models.

That’s why Pharma insiders are already taking notice. Axiom’s charts could’ve predicted—and maybe prevented—Pfizer’s liver-troubled obesity pill danuglipron, Agios’s mitapivat, and Third Harmonic’s KIT inhibitor.

The company already has pilot projects with six major drugmakers.

Of course, Axiom’s not alone in this frontier—a wave of startups like Vivodyne, GATC Health, and Insilico are racing to use AI and human-cell models to make animal testing obsolete.

Sci-Fi Smashes Into Biotech

White’s vision for the future is sci-fi: where we simulate biology before we touch it, where every drug is pre-tested in silico on a virtual liver before a single human swallows it.

But, unlike most sci-fi visions, nobody’s laughing at it. Because AI is already showing it’s possible.

The same type of intelligence that helped me decode my own body is now being applied to the global drug pipeline—with exponentially higher stakes.

What excites me most about AI isn’t the chatbots or stock trades—it’s watching it take a wrecking ball to our overpriced, overprescribed, underperforming healthcare system.

It’s not about replacing doctors or scientists. It’s about giving them radar. A copilot that sees patterns too complex for human eyes.

For me, it meant understanding my own biology. For Brandon White, it means preventing billions of dollars in drug failures—and saving lives.

Different scales. Same revolution.

Right now, a new type of intelligence is learning the language of our cells. And beneath the surface, it’s already making waves.

As usual, we’re on the hunt for new opportunities in this space.

(In fact, our Paradigm Mastermind Group members might get one soon enough.)